Three of the most deadly cancers get critical funding for research

Immunotherapy for leukemia patients has been nothing short of a miracle. Now scientists hope to use that science and other forms of gene therapy to tackle three of the deadliest forms of cancer: glioblastoma (brain cancer), sarcoma (bone cancer) and ovarian cancer. Three scientists have received $1.3 million in critical funding from the Alliance for Cancer Gene Therapy (ACGT), the nation's only nonprofit dedicated exclusively to cell and gene therapies for cancer. These new grants will be used to study immunotherapy and virotherapy in the treatment of glioblastoma, sarcoma and ovarian cancer.

"We have big hopes for these grants," said John Walter, CEO and president of ACGT. "ACGT was one of the first funders to support Dr. Carl June's work at the University of Pennsylvania in successfully treating leukemia with gene therapy when it was still deemed 'risky' science. The recent FDA approval of the first gene therapy treatment to come out of this research, Kymriah, validates the promise of this science. With these three new clinical investigator grants, we hope to see similar results with immunotherapy and virotherapy in treating hard-to-combat solid tumor cancers."

The new grants are:

Nori Kasahara, MD, PhD - Virotherapy for Glioblastoma Brain Cancer
Co-Leader Viral Oncology Program
Sylvester Comprehensive Cancer Center, University of Miami

Dr. Kasahara's research focuses on translational application of gene transfer technologies to cancer, transplantation and regenerative medicine. Dr. Kasahara will use his ACGT grant to advance a clinical trial for a virotherapy for glioblastoma. Using a modified retrovirus to deliver chemotherapy directly into cancer cells, these "suicide genes" continue to replicate to prevent recurrence. The work will take the experience in the lab and translate it to a patient clinical trial.

Seth Pollack, M.D. - Immunotherapy for Sarcoma
Fred Hutchinson Cancer Research Center, Seattle, Washington

Dr. Pollack's research is focused on developing novel immunotherapies for patients with advanced sarcoma, specifically synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL). Dr. Pollack's ACGT grant will further his research by using immunotherapy to target this rare form of cancer that grows in connective tissue - cells that support other body tissues such as in bones, muscles, tendons, etc. The initial clinical trial will deploy two different types of genetically engineered T cells to target the cancer and to assess efficacy and safety.

Daniel Powell, Jr., PhD - Immunotherapy for Ovarian Cancer
Director of Immunotherapy for Division of Gynecology
University of Pennsylvania Perelman School of Medicine

Dr. Powell's research focuses on the development of innovative immunotherapeutic strategies, including adoptive immunotherapy, using chimeric antigen receptor (CAR) T cells. Dr. Powell will used his ACGT grant to enroll nine ovarian cancer patients in a new clinical trial. Immune system killer T cells will be developed outside the body and reinserted to establish an offense against the disease and a defense against recurrence.

"ACGT's Clinical Investigator grants allow these scientists to advance their research from the laboratory to the bedside for patients in clinical trials, providing for an opportunity to see these treatments work in actual patients and hopefully save lives," noted Walter. "Our goal at ACGT is to truly make an impact on how cancer is treated through the use of gene and cell therapies so that one day, cancer will be a treatable and manageable disease."

ACGT has now issued a total of 55 grants, including 19 clinical translation grants and 36 Young Investigator grants totaling more than $28 million. This is particularly exciting given ACGT's commitment to contributing 100 percent of donations directly to research. ACGT-funded work is also attracting increasing attention from the pharmaceutical industry, which is swiftly discovering the potential of cell and gene therapies.

About Alliance for Cancer Gene Therapy (ACGT)
Established in 2001, ACGT is the nation's only non-profit dedicated exclusively to cell and gene therapy treatments for all types of cancer. One hundred percent of contributions go directly to research. Founded by Barbara Netter and her late husband Edward, ACGT was created to conduct and accelerate critically needed innovative research.

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

Researchers develop a new method for turning skin …

Our bodies consist of many different kinds of cells, each with their own role. The Japanese scientist Shinya Yamanaka had made earlier the discovery, earning the Nobel Pr...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...

Human clinical trial reveals verapamil as an effec…

Researchers at the University of Alabama at Birmingham Comprehensive Diabetes Center have discovered a safe and effective novel therapy to reduce insulin requirements and...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

New small molecules pave the way for treating auto…

The innate immune system is the first line of defense, with cells that quickly identify "foreign" motifs from viruses and bacteria and mount up a counterattack to elimina...

How targeting metabolism can defeat cancer stem ce…

Researchers are the University of Michigan Rogel Cancer are unraveling a crucial thread that explains why cancer so often becomes resistant to treatment. In a breakthroug...

Amgen and MBC Biolabs announce winners of the Amge…

Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) announced that Delve Therapeutics and Mitokinin have won the Amgen Golden Ticket at MBC BioLabs. Each company recei...

FDA warns of imposters sending consumers fake warn…

The U.S. Food and Drug Administration is warning consumers about criminals forging FDA warning letters to target individuals who tried to purchase medicines online or ove...